Physician profile
Rajeev Raghavan
NPI 1851599740
$157,979.15
in general payments reported to CMS, 2019-2025
38 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $3,930 · 2021: $18K · 2022: $11K · 2023: $18K · 2024: $78K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Consulting Fee: $45K · Food and Beverage: $5,489 · Travel and Lodging: $2,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,017.50 |
| Consulting Fee | $44,737.50 |
| Food and Beverage | $5,489.45 |
| Travel and Lodging | $2,788.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58,805.48 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $55,837.04 | 2020-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,223.54 | 2022-2024 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $13,699.45 | 2021-2023 | |
| Travere Therapeutics, INC. | $7,751.94 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $3,625.30 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $636.04 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $490.07 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $361.83 | 2022-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $349.95 | 2020-2025 | Acthar |
| Janssen Pharmaceuticals, INC | $206.70 | 2022-2023 | Xarelto |
| Vifor Pharma, INC. | $205.00 | 2019-2023 | Veltassa |
| Horizon Therapeutics Plc | $193.64 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $191.71 | 2019-2025 | Jynarque |
| Outset Medical INC | $139.18 | 2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $128.75 | 2024 | |
| Fresenius USA Marketing, INC. | $120.31 | 2019-2025 | Nxstage System One, Nxstage Cartridge Express, Optiflux |
| Aurinia Pharma U.S., INC. | $107.16 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $100.00 | 2019 | |
| Recor Medical INC | $99.17 | 2025 | Paradise Ultrasound Renal Denervation System |
| Baxter Healthcare | $97.59 | 2020 | |
| Ani Pharmaceuticals, INC. | $72.46 | 2023-2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $63.62 | 2021-2025 | Proclaim, Cardiomems |
| Ardelyx, INC. | $61.98 | 2025 | Ibsrela |
| Kaneka Medical America LLC | $56.87 | 2019 | |
| Akebia Therapeutics INC | $44.61 | 2021-2025 | Vafseo |
| Exact Sciences Corporation | $42.45 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $38.09 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $37.17 | 2025 | Inspire |
| Novo Nordisk INC | $27.23 | 2025 | Wegovy |
| Apellis Pharmaceuticals, INC. | $23.88 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $23.82 | 2023 | Gattex |
| Genzyme Corporation | $23.17 | 2023 | |
| Paratek Pharmaceuticals, INC. | $22.05 | 2023 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $19.15 | 2025 | Tryvio |
| Inari Medical, INC. | $18.96 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Philips North America LLC | $17.63 | 2025 | Vest Therapy Und |
| Antares Pharma, INC. | $16.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Raghavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.